stockrow
Saturday 7 November 2026
Export SPTX’s income statement to Excel — free account
Seaport Therapeutics, Inc
SPTX Healthcare Biotechnology
- EPS
- +94.8%
- Free cash flow
- −43.8%
Quarter to September 2026, against a year earlier
21.18
0.79
+3.87%
Follow SPTX
Alert me
| Dec '25 | Dec '24 | |
|---|---|---|
Current Ratio |
17.46 | 27.82 |
Net Debt/EBITDA |
2.42 | 5.91 |
Debt/Assets |
0.00% | 0.11% |
Debt/Equity |
0.00 | (0.01) |
Asset Turnover |
0.00 | — |
Operating CF/Net income |
1.04 | 0.63 |
Capex/Depreciation |
0.18 | (0.53) |
| 127.57% | 0.00% | |
| (26.52%) | 0.00% | |
ROIC |
(324.62%) | 0.00% |
Return on Tangible Assets |
(35.51%) | (15.67%) |
Research and Development Expense of Revenue |
0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% |
Free Cash Flow per Share |
(32.98) | (31.54) |
Cash per Share |
90.98 | 327.78 |
Shareholders Equity per Share |
98.06 | (26.35) |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
98.06 | (26.35) |
Free Cash Flow |
(78.30) | (29.74) |
Working Capital |
210.45 | 299.00 |
Capital Expenditures |
(0.36) | (0.11) |
Net Current Asset Value |
207.00 | (30.47) |
| Other line items | ||
Quick Ratio |
16.90 | 27.72 |
Depreciation/Fixed assets |
(4.91) | 0.89 |
Cash ROIC |
(17.45%) | (10.45%) |
Accounts Payable Turnover |
0.00 | — |
Average Days of Payables |
0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 |
Operating CF per Share |
(32.83) | (31.42) |
Capex per Share |
(0.15) | (0.12) |
Average Payables |
3.37 | — |
Average Assets |
282.39 | — |
Average Common Equity |
(58.70) | — |
Capex to Sales |
0.00 | 0.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026